$CMPS

Compass Pathways presented real-world analyses showing that treatment-resistant depression (TRD) has significant economic burden during treatment-resistant episodes, with costs declining as patients stabilize. Their psilocybin formulation, COMP360, showed sustained clinical benefit in phase 3 trials, with 25% and 39% of participants achieving meaningful symptom reduction in COMP005 and COMP006, respectively, maintained through week 26.

Compass Pathways (CMPS) granted equity awards to 11 employees, including options for 218,900 shares and restricted share units for 104,200 shares. The options have exercise prices of $12.44 and $11.95, vesting over four years. The awards were approved by the Board's Compensation Committee as inducements for employment.

Psychedelics show promise for treating depression with rapid, durable effects. Compass Pathways' COMP360 and Definium Therapeutics' DT120 have shown positive phase 3 results. Lilly agreed to acquire AtaiBeckley for up to $3.8B, highlighting growing interest. Regulatory advances and clinical data are shifting sentiment, but operational hurdles remain.

Compass Pathways (CMPS) appointed Kelley Boucher as Chief People Officer. She will oversee the company's people strategy as it prepares for the potential launch of COMP360 psilocybin, subject to FDA approval, in early 2027. Boucher has extensive experience in biotechnology and healthcare, previously serving as Chief People Officer at Apellis Pharmaceuticals and holding senior HR roles at Alnylam Pharmaceuticals, Abiomed, and Shire.

Compass Pathways (CMPS) reported positive Phase III trial results for its psilocybin-based depression treatment, COMP360, with 40% of patients showing clinical improvement. The company aims for a 2027 launch, pending FDA approval and psilocybin rescheduling. Compass is also advancing trials for PTSD and exploring other mental health indications.

Definium Therapeutics (DFTX) and Compass Pathways (CMPS) are in focus due to a White House push to accelerate psychedelic therapy research. Both companies are developing late-stage psychedelic therapies for psychiatric conditions. DFTX has a 62% upside with a $36.67 price target, while CMPS has a 227% upside with a $21.75 target. Both companies welcomed the executive order and highlighted their ongoing clinical trials.

COMPASS Pathways' psychedelic therapy for treatment-resistant depression is nearing FDA approval, with phase III trials showing rapid and durable efficacy. The company targets a 2027 launch, citing strong payer interest, robust infrastructure, and a large unmet patient need. A PTSD program is also advancing, according to a Morgan Stanley conference transcript.

COMPASS Pathways (CMPS) presented at Morgan Stanley's conference, targeting a 2027 launch for its psilocybin-based drug COMP360. The company reported strong clinical data, FDA progress, and a ready treatment network. Shares are up 171% year-to-date, trading near a 52-week high at $14.13, with a $1.96B market cap.

FDA held meetings on psychedelic drug development and PDUFA reauthorization. Definium reported successful Phase 3 trial data for its LSD drug, aiming for FDA approval. Biopharma companies presented positive lung cancer survival data. Novartis' asset stumbles caused a 13% share price drop.

The FDA will hold a public hearing on psychedelic drugs' therapeutic use, part of a Trump administration push to accelerate development. The FDA has issued priority vouchers to three companies. The hearing will discuss practical issues like training and safety data. FDA officials published a framework for psychedelic drug approval, suggesting flexible trial designs. Industry executives say this could reduce regulatory delays and benefit companies like AtaiBeckley, Compass Pathways, and Definium